Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos    GLPG   BE0003818359

GALAPAGOS (GLPG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
87.08(c) 87.84(c) 87.92(c) 89.74(c) 91.34(c) Last
174 425 208 483 295 223 699 357 580 341 Volume
+0.83% +0.87% +0.09% +2.07% +1.78% Change
More quotes
Financials (EUR)
Sales 2018 196 M
EBIT 2018 -133 M
Net income 2018 -162 M
Finance 2018 936 M
Yield 2018 -
Sales 2019 227 M
EBIT 2019 -87,6 M
Net income 2019 -97,3 M
Finance 2019 787 M
Yield 2019 0,18%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 18,8x
EV / Sales2019 16,9x
Capitalization 4 607 M
More Financials
Company
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies.It operates through the Research and Development and Fee-for-Services segment.The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June... 
More about the company
Surperformance© ratings of Galapagos
Trading Rating : Investor Rating :
More Ratings
Latest news on GALAPAGOS
07/21MorphoSys, Galapagos ink global license pact with Novartis Pharma to develop ..
AQ
07/20MORPHOSYS : Novartis demonstrates commitment to lead immuno-dermatology by in-li..
AQ
07/20MORPHOSYS : and Galapagos Sign Global License Agreement for MOR106 with Top Phar..
AQ
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/19GALAPAGOS : MorphoSys and Galapagos Sign Global License Agreement for MOR106 wit..
GL
07/19MORPHOSYS : and Galapagos Sign Global License Agreement for MOR106 with Top Phar..
AQ
07/12GALAPAGOS : Reports Summarize Atopic Dermatitis Findings from Galapagos N.V. (Ne..
AQ
07/09GALAPAGOS : announces design for PINTA Phase 2 trial with GLPG1205 in IPF
GL
07/02GALAPAGOS : Servier and Galapagos announce start of global ROCCELLA Phase 2 clin..
AQ
06/29European stocks shrug off trade worries with quarterly gain
RE
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/20Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug
1
07/19Top 3 today -- #1 Going deeper into the ezcema game, Novartis orchestrates $1..
2
07/19Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug  
07/19Novartis to Pay as Much as $1 Billion for Rights to Skin Drug: Novartis AG ag.. 
07/19Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys  
More tweets
Qtime:113
News from SeekingAlpha
03/26JF'S CORE BIOTECH BUYS #8 : Taking Advantage Of Volatility And Initiating A Posi.. 
03/20JF'S CORE BIOTECH BUYS EDITION 1 VOL : Updates And Taking Advantage Of Current W.. 
03/19BIOTECH BIO SERIES #2 : Is Gilead Still A Growth Stock? 
03/13ROAD TO FINANCIAL INDEPENDENCE : My February 88-Stock Portfolio Review With Big .. 
03/12JF'S CORE BIOTECH BUYS EDITION 1 VOL : Buying Weakness In 2 Beaten Down Stocks 
Chart GALAPAGOS
Duration : Period :
Galapagos Technical Analysis Chart | GLPG | BE0003818359 | 4-Traders
Technical analysis trends GALAPAGOS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 104 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS15.65%5 399
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.17%21 355
INCYTE CORPORATION-25.97%14 861
SEATTLE GENETICS, INC.31.33%11 158